Telomerase is a ribonucleoprotein enzyme that maintains protective structures at the ends of eukaryotic chromosomes. We examined the impact of telomerase inhibition by the dominant-negative human catalytic subunit of telomerase (DN-hTERT) on the biological features of acute leukemia. We introduced vectors encoding dominant-negative (DN)-hTERT, wild-type (WT)-hTERT, or a control vector expressing only a drug-resistant marker into a telomerase-positive human acute lymphoblastic leukemia cell line, HAL-01. Expression of DNhTERT dramatically inhibited telomerase activity, leading to apoptotic cell death. Mutant telomerase expression also enhanced daunorubicin-induced apoptosis. Nude mice (n = 5 per group) received subcutanous implants of HAL-01 cells expressing the control vector or DN-hTERT or WT-hTERT. Implantation of HAL-01 cells expressing control vector (n = 5) rapidly produced tumors, whereas implantation of those expressing DN-hTERT (n = 5) did not. Thus, telomerase inhibition both growth of HAL-01 cells in vitro and tumorigenic capacity in vivo. Furthermore, the G-quadruplex-interactive telomerase-specific inhibitor, telomestatin, shortened the telomere length and induced apoptosis in freshly isolated primary acute leukemia cells. These results suggest that antitelomerase therapy may be useful in some acute leukemias in combination with antileukemic agents such as daunorubicin.
Introduction
Telomerase is a cellular RNA-dependent DNA polymerase that serves to maintain the tandem arrays of telomeric TTAGGG repeats at eukaryotic chromosome ends. 1 Telomeres are highly conserved in organisms ranging from unicellular eukaryotes to mammals, indicating the widespread utility of their protective mechanisms for preventing chromosomal ends from undergoing degradation and ligation with other chromosomes. 1 Without telomeric caps, human chromosomes would undergo end-toend fusions, with the formation of dicentric and multicentric chromosomes. 2, 3 These abnormal chromosomes would break during mitosis, resulting in severe damage to the genome and activation of DNA damage checkpoints, leading to cell senescence or the initiation of apoptotic cell death pathways. 4 Indeed, it has been proposed that telomere length specifies the number of cell divisions that a cell can undergo prior to senescence. 2 There has been great progress in the regulation of telomeres and telomerase in normal and malignant hematopoietic cells. [5] [6] [7] [8] [9] [10] Telomerase activity is upregulated in at least 80% of acute leukemic cells. 8, 9 The increased telomerase activity in stimulated B cells is associated with increased expression of the human catalytic subunit of telomerase (hTERT). 11 In addition, the induction of telomerase activity in human progenitor cells is dependent on growth-factor-mediated signals such as p38 mitogen-activated protein kinase and phosphatidylinositol 3'-kinase. 12 It has been shown that expression of hTERT in cultured human primary cells reconstitutes telomerase activity and allows immortal growth. [13] [14] [15] [16] Furthermore, TERT-mediated telomerase activation is able to cooperate with oncogenes in transforming cultured primary cells into neoplastic cells. 17 In addition, TERT-driven cell proliferation results in activation of the c-myc oncogene. 18 These findings in cultured cells have suggested the possibility that telomerase upregulation may contribute actively to tumor growth. 19 In contrast, inhibition of telomerase in tumor cells should disrupt telomere maintenance and cause malignant cells to enter proliferative crisis, followed by senescence or cell death. Genetic experiments using a dominant-negative form of human telomerase have demonstrated that telomerase inhibition can result in telomere shortening followed by proliferation arrest and apoptotic cell death. 20, 21 This makes telomerase a target not only for cancer diagnosis but also for the development of novel therapeutic agents. We examined the impact of telomerase inhibition by dominant-negative (DN)-hTERT on the biological features of acute leukemia cells. We found that inhibition of telomerase activity induced apoptosis and sensitivity to some chemotherapeutic reagents in acute leukemia cells.
Materials and methods
Generation of stable clones expressing wild-type (WThTERT and DN-hTERT mutants HAL-01 cells (a human acute lymphoblastic leukemia cell line) were derived as described previously. 22 The expression vectors (pBABE, pBABE-WT-hTERT, pBABE-DN-hTERT) were a gift from Dr Robert Weinberg (Massachusetts Institute of Technology). HAL-01 cells were cultured in RPMI1640 medium (Life Technology, Inc., Rockville, MD, USA) supplemented with 10% fetal calf serum (Hyclone Laboratories, Logan, UT, USA). HAL-01 cells were transfected with the expression vectors pBABE, pBABE-WT-hTERT, or pBABE-DN-hTERT, by electroporation. 23 Beginning 48 h after electroporation, cells were selected with 2 mg/ml puromycin and cloned by limiting dilution. Population doubling (PD) 0 was defined as the time at which cultures reached confluence in 10-cm culture dishes.
Telomerase assay and measurement of terminal restriction fragments (TRF)
Telomerase activity was measured by a telomere repeat amplification protocol (TRAP) assay using a TRAPeze telomerase detection kit (Oncor, Gaithersburg, MD, USA). 24, 25 PCR products were subjected to 12% acrylamide denaturing electrophoresis in an automated laser fluorescence DNA sequencer (model II, Pharmacia LKB Biotechnology, San Diego, CA, USA) and analyzed by the Fragment Manager program (Pharmacia LKB Biotechnology). 24, 25 Activity in the extractbased polymerase chain reaction (PCR) TRAP assay was detected as a periodic 6-bp peak of telomerase products; in each sample, relative telomerase activity was determined semiquantitatively in comparison with a 36-bp internal standard. 24, 25 To measure TRF, genomic DNA was digested with restriction enzymes (Hinfl or Rsal) fractionated on 0.7% agarose gels, and transferred to nylon membranes. Hybridization was performed with the Telo TTAGGG telomere length assay kit (Roche Molecular Biochemicals, Mannheim, Germany). The smears of the developed films were captured on an Image Master (Pharmacia Biotech, Uppsala, Sweden), and telomeric length was assessed quantitatively. We then defined the TRF in each sample as peak intensity of the telomeric length, in kilobases, by densitometry. 26 Apoptotic effects in DN-hTERT mutant HAL-01 cells treated with antileukemic agents Daunorubicin (DNR), etoposide (VP-16), vincristine (VCR), 6-mercaptopurine (6-MP), and methotrexate (MTX) were obtained from Sigma (St Louis, MO, USA). Either DN-hTERT-or WThTERT-expressing HAL-01 cells were cultured up to PD10 with the indicated concentration of antileukemic agents for 48 h. After treatment, the occurrence of apoptosis was determined by flow cytometric analysis with FITC-conjugated APO2.7 monoclonal antibody. 27 
Transformation assay
In all, 10 000 viable HAL-01 cells transfected with pBABE-puro (clone 1), pBABE-puro-WT-hTERT(clone 1), or pBABE-puro-DNhTERT (clone 2) were injected into 4-week-old nude mice (n ¼ 5 per each group) (BALB/c nu/nu).
Primary leukemic cells
The primary leukemic blasts were freshly isolated from four patients with acute myeloid leukemia (AML-M2) who had been referred to Tokyo Medical University Hospital in 2002. All patients provided informed consent before the studies were conducted.
Fluorescence in situ hybridization and quantitative image analysis
Telomere length measurements of primary leukemia cells were performed by flow-FISH as described previously. 10, 28 The primary cells were washed in phosphate-buffered saline, and divided equally into two 1.5-ml tubes. After centrifugation for 15 s at 15 000 g, the supernatant was removed and the cell pellets were resuspended in the hybridization mixture (10 5 cells/ml), which consisted of 70% deionized formamide (Gibco BRL, Rockville, MD, USA), 20 mm Tris, and 1% bovine serum albumin, with 0.3 mg/ml telomere-specific FITC-conjugated PNA probe (DAKO, Denmark). After heat denaturation of DNA for 10 min at 821C, followed by hybridization for 2 h at room temperature in the dark, the cells were washed three times and resuspended in DNA-staining solution with propidium iodide and RNase A. The samples were then analyzed by flow cytometry (EPICSXL Beckman Coulter, Fullerton, CA, USA). We compensated for daily shifts in the linearity of the flow cytometer and fluctuations in the laser intensity and alignment by using FITC-labeled fluorescent beads (Quantum-24 Premixed; Flow Cytometry Standards, San Juan, Puerto Rico, Brazil). To assess the day-to-day variation in flow-FISH results, aliquots of cells derived from primary calf thymus cells were analyzed in each experiment.
Statistical analysis
Comparisons between groups were analyzed using Student's ttest. Values of Po0.01 were considered to indicate statistical significance. Statistical tests were performed with the Microsoft Word Excel software package (Brain Power, Calabashes, CA, USA) for a Macintosh personal computer.
Results

Effects of DN-hTERT on telomerase activity and telomere length
Previous reports have identified several point mutants in reverse transcriptase motifs of the telomerase catalytic subunit hTERT that exhibit dramatically reduced telomerase activity. 20, 21 To study the effects of long-term expression of DN-hTERT in the human telomerase-positive acute leukemia cell line HAL-01, we introduced DN-hTERT. WT-hTERT, or a control vector expressing only a puromycin-resistant marker into HAL-01 cells. After puromycin selection, successfully transfected cells were isolated. We selected clones expressing DN-hTERT (clones 2, 3, 5), or WT-hTERT (clones 1. 2). or a control vector (clones 1, 2) for the TRAP assays ( Figure 1a ). We investigated telomerase activity in these clones. Expression of DN-hTERT in HAL-01 cells (clones 2, 3, 5) dramatically reduced telomerase activity ( Figure 1a ). In contrast, expression of WT-hTERT (clones 1, 2) did not increase overall telomerase activity in HAL-01 cells ( Figure 1a) . Thus, expression of a catalytically inactive hTERT mutant results in the disruption of telomerase activity in HAL-01 cells. We next determined whether inhibition of telomerase activity influenced telomere length in the HAL-01 cell line (Figure 1b) . We assessed peak telomere length in HAL-01 cell clones expressing either DN-hTERT (clone 2), or WT-hTERT (clone 1), or a control vector (clone 1) (Figure 1b) . The telomeres in HAL-01 cells expressing control vector (clone 1) were maintained at 6.8 kb in length. As the HAL-01 clones expressing DN-hTERT (clone 2) were passaged, gradual telomere shortening was observed (Figure 1b) . Whereas WT-hTERT (clone 1) -or control-vector (clone 1)-expressing cells grew successfully in culture, DN-hTERT-expressing cells (clones 2, 3) showed loss of viability (see below). Therefore, we harvested DN-hTERTexpressing cells (clone 2) on PD 35. We estimated that DNhTERT-expressing cells on PD35 (clone 2) lost 4.1 kb in telomere length from the time of transfection (Figure 1b) . As the process of isolating clones expends approximately 20 PD, the loss of telomere sequence per PD in DN-hTERT-expressing clone 2 was 74 bp. In contrast, cells expressing WT-hTERT (clone 1) showed a stable telomere length of 6.8 kb (Figure 1b) . Similar results were obtained in two independent experiments.
Inhibition of telomerase activity, slowing of growth, and induction of apoptosis The telomerase-inhibited HAL-01 cells (clone 2) also exhibited morphological changes accompanied by apparent cell death over PD35. HAL-01 cells expressing control vector (clone 1) (Figure 3a) or WT-hTERT (clone 1) (Figure 3b ) exhibited similar morphologies, but the entire population of DN-hTERT-expressing HAL-01 cells (clone 2) exhibited cytoplasmic blebbing and chromatin condensationFmorphologic features of apoptosis (Figure 3c and d) . These results demonstrate that the expression of DN-hTERT in HAL-01 cells inhibits telomerase activity, resulting in further telomere shortening, which may lead to chromatin damage and the subsequent induction of apoptosis.
Enhancement of drug-induced apoptosis in early passages of DN-hTERT-expressing HAL-01 cells
In early passages, DN-hTERT-expressing HAL-01 cells (PD10) did not show increased apoptosis, so we examined the combination of telomerase inhibition and chemotherapeutic agents (Table 1) . To assess the effects of telomerase inhibition in Figure 1 Effects of WT-hTERT and DN-hTERT on telomerase activity and telomere length in HAL-01 cells. (a) Telomerase activity was measured by a telomere repeat amplification protocol (TRAP) assay with a TRAPeze telomere detection kit (Oncor, Gaithersburg, MD, USA). 24, 25 Each set of peaks corresponds to telomeric repeats that were synthesized by telomerase in cell extracts obtained from HAL-01 cells (Vector, Cl and C2; WT-hTERT, Cl and C2; DN-hTERT, C2, C3, and C5). Similar results were obtained in two independent experiments. (b) Total genomic DNA from HAL-01 cells was assessed for telomere restriction fragment size by Southern blot analysis with a telomeric probe (Vector, Cl; WT-hTERT, Cl; DN-hTERT, C3). Left margin, molecular-sized marker (kb). Similar results were obtained in two separate experiments. 
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A Nakajima et al modulating responses to chemotherapeutic agents, we focused our experiments on early passages of HAL-01 cells expressing either DN-hTERT (PD10) or WT-hTERT (PD10). HAL-01 clones expressing DN-hTERT or WT-hTERT were cultured with the chemotherapeutic agents for 48 h, after which the frequency of apoptosis was determined by the use of APO2.7 antibody (Table 1) . DN-hTERT-expressing HAL-01 cells showed greater induction of apoptosis in response to DNR than did WT-hTERTexpressing cells (Table 1) , but no significant difference in sensitivity to VP-16 was observed in HAL-01 cells expressing either DN-hTERT or WT-hTERT in three independent experiments (Table 1) . Further, we examined the chemosensitivity of DN-hTERT-expressing HAL-01 cells (PD10) after exposure to VCR, 6-MP, or MTX. There was no enhanced chemosensitivity after exposure to VCR, 6-MP, or MTX compared with the WThTERT or control-vector-expressing HAL-01 cells (data not shown). These results suggest that combined use of DNR and telomere-maintenance inhibition could be an effective therapeutic approach in acute leukemia.
Effect of DN-hTERT on in vivo tumorigenicity
Inhibition of cell growth and reduction of apoptosis in vitro indicated that inhibition of telomerase activity should reduce the tumorigenicity of cells in vivo. This was confirmed in nude Telomere shortening and induction of apoptosis in primary acute leukemia cells after exposure to the telomerase inhibitor telomestatin
The G-quadruplex-interactive telomerase specific inhibitor, telomestatin, has been described previously. 29, 30 We examined the effects of telomerase inhibition on primary leukemic blasts freshly isolated from the bone marrow of four patients with acute myeloid leukemia (AML-M2). All patients provided informed consent prior to the studies being conducted. The blast cells were incubated in suspension cultures in the absence or presence of 5 mm telomestatin for 10 days, and telomere length was determined by flow-FISH analysis (Figure 5a ). This assay permits the examination of telomere length in a small number of cells. The occurrence of apoptosis in suspension cultures for 10 days was also examined by the use of APO2.7 monoclonal antibody (Figure 5b ). Telomestatins induced telomere shortening in primary blast cells in all cases (Figure 5a ). Telomestatin also induced apoptosis at high rates (APO2.7 positivity from 21 to 64%), accompanied by significant telomere shortening (TRF 7.26-4.57 kb) in the blast cells from case 4 (Figure 5a, b) . These results suggest that telomere shortening by telomestatin induces apoptosis in some primary blast cells of acute leukemia.
Discussion
Roles for transcriptional control of hTERT or alternative splicing of hTERT have recently been postulated. [31] [32] [33] [34] [35] Several alternatively spliced variants of hTERT have been identified, including two deletions (a and b) and four insertions of intron sequences into hTERT mRNA. 34, 35 Although all known splice variants of hTERT are inactive, the observation that hTERTa is a dominantnegative inhibitor of telomerase indicates that splicing may indeed represent a means for cells to fine-tune their levels of active enzyme by differentially shifting the balance between the hTERTa form and the full-length transcript. 34, 35 Point mutations of hTERT protein have emerged as an additional mechanism of regulating telomerase activity. 36 Telomerase activity can be abolished by replacement of any of the three conserved aspartic acid residues of amino-acid motifs A and C to the hTERT subunits in budding yeasts and in humans. 36 Ectopic expression of these hTERT mutants in human cancer cells results in telomerase inhibition, telomere shortening, and apoptosis. 20, 21 Therefore, these mutant hTERT subunits act as dominant negatives of wild-type hTERT and appear to be effective tools for studying the characteristics of telomerase.
We observed that inhibition of telomerase by DN-hTERT in human acute leukemia cells reproducibly caused not only telomere shortening but also induction of apoptosis (Figures 1-3) . DN-hTERT-expressing HAL-01 cells (C2. C3) showed a 10-fold increase in APO2.7 positivity at day 50 compared with day 30 (Figure 2 ). These results suggest that telomerase activity is the dominant mechanism providing telomere maintenance and long-term viability to the human leukemia cell line. We have not identified cells that survive the period of crisis induced by 
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A Nakajima et al DN-hTERT, but Sachsinger et al 37 demonstrated that telomerase activity was efficiently reactivated in murine RenCa cells expressing DN-mTERT and suggested that there were fundamental differences in telomere regulation between human and murine cells. 37 In contrast to DN-hTERT-expressing cells, expression of WT-hTERT (clones 1, 2) did not increase overall telomerase activity in HAL-01 cells (Figure 1a) . Telomerase hTR subunits are expressed in most tissue cells, whereas expression of hTERT is generally restricted to replicating cells through largely undefined mechanisms. 38 Although a modest increase in hTR expression is apparent in stimulated T cells, 39 the increase in telomerase activity in stimulated B cells is associated with increased expression of hTERT. 11 The lack of increase in telomerase activity in WT-hTERT-expressing HAL-01 cells could not be resolved in this study, but it may be due to limited hTR expression or other factors.
Although inhibition of telomerase by DN-hTERT is very effective and selective in vitro, the gene therapy method limits the proportion of completely telomerase-negative clones. Several other strategies to inhibit telomerase activity have been reported so far. Strategies that target the RNA subunit of telomerase with antisense RNA or peptide nucleic acids diminish cellular telomerase activity and induce some changes in cellular growth. 40, 41 Recent studies have described nonnucleosidic small-molecule telomerase inhibitors (BIBR1532 and BIBR1591) and the G-quadruplex-interactive telomerasespecific inhibitor (telomestatin), for which preclinical trials are planned. 29, 30, 42 . We, too, observed that the telomerase-specific inhibitor telomestatin induced telomere shortening and apoptosis in freshly obtained acute leukemia cells (Figure 5a, b) . Since telomestatin selectively stabilizes intramolecular G-quadruplexes, including that produced from the human telomeric sequence d[T2AG3]4, telomestatin might lead to more rapid onset of telomere shortening, chromosomal instability, cell crisis, and apoptosis. 30 However, it is too early to know with certainty whether telomestatin will become a treatment option for human leukemia, since there is concern about side effects on normal hematopoietic cells and germ cells. 43 Lee et al reported that neoplastic cells from telomerase-RNA null mice (mTERCÀ/À) showed enhanced chemosensitivity to DNR or related double-strand DNA-break (DSB)-inducing agents. 44 Telomere dysfunction, rather than telomerase inhibition, is proposed to be the principal determinant governing chemosensitivity. specifically to DSB-inducing agents. 44 We observed two-fold enhanced induction of apoptosis by DNR at 50 and 100 nm in DN-hTERT-expressing HAL-01 cells compared with WT-hTERT-expressing cells, whereas significant chemosensitivity was not observed in cells exposed to VP-16 (Table 1) . We were unable to detect enhanced induction of apoptosis by VCR, 6-MP, or MIX in DN-hTERT-expressing HAL-01 cells (data not shown). VP-16 is a topoisomerase II inhibitor and induces DSB similarly to DNR. Therefore, it will be important to determine why these two different kinds of DSB-inducing agents have different effects on chemosensitivity in DN-hTERT-expressing HAL-01 cells. Although the exact mechanism of this enhanced induction of apoptosis in DN-hTERT-expressing cells requires further elucidation, certain antineoplastic agents may enhance telomere-position effects in neoplastic cells. 45 We did not determine the telomere dysfunction in HAL-01 cells, but the appearance of DN-hTERT-expressing HAL-01 cells at PD10 is enough to show cytotoxic synergy with DNR ( Figure 1b and Table 1 ).
There have also been concerns that inhibition of telomerase might lead to an increase in malignancy by enhancing the genomic instability of cells. 46 These concerns have arisen from Telomere shortening and induction of apoptosis in primary leukemia cells after exposure to telomestatin. (a) Primary leukemia cells were freshly isolated from four patients with acute myeloid leukemia (AML-M2). Primary leukemia cells were incubated for 10 days in RPMI1640 medium with 20% fetal calf serum in the absence or presence of 5 mm telomestatin (gift from Dr Kazuo Shinya, The University of Tokyo). Telomere length was determined by flow-FISH analysis. (b) Primary leukemia cells were cultured for 10 days in RPMI1640 medium with 20% fetal calf serum in the absence or presence of 5 mm telomestatin. The incidence of apoptosis was determined by APO2.7 antibody.
Telomerase inhibition in acute leukemia cells A Nakajima et al observations of mTRÀ/À knockout mice, which have an increased incidence of malignancy in both early and late generations, particularly in the setting of p53 mutation. 46 However, there is no evidence to suggest that this would be the case in humans. 47 Although a critical and careful evaluation of telomerase inhibitors in clinical development is certainly required, inhibition of telomerase activity appears to be a potential approach for the treatment of leukemia. This work suggests that telomerase inhibition may serve as an effective tool for eliminating leukemia cells. These experiments await the development of specific inhibitors of the components of the telomerase complex.
